ERAP1: A Promising Target for Cancer and Other Diseases (G51752)

Target Name: ERAP1

NCBI ID: G51752

ERAP1

ERAP1: A Promising Target for Cancer and Other Diseases

ERAP1 (endoplasmic reticulum-associated protein 1) is a protein that is expressed in most tissues of the body. Its primary function is to transport various proteins from the endoplasmic reticulum to the cytoplasm, where they can be involved in various cellular processes.

One of the functions of ERAP1 is to transport the protein known as ALAP (alpha-latency phosphorylated), which is a protein that is involved in the regulation of cell cycle progression. ALAP is a key regulator of the G1 phase of the cell cycle, which is the phase of growth and development when the cell prepares for cell division.

Research has shown that ERAP1 is a drug target for various diseases, including cancer. One of the reasons for this is that ERAP1 has been shown to be highly expressed in many types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that inhibiting ERAP1 can lead to a reduction in the growth and survival of cancer cells.

Another potential mechanism by which ERAP1 may be involved in cancer is its role in the development of metastasis. ERAP1 has been shown to be involved in the regulation of cell migration, which is a critical step in the development of metastasis. Additionally, studies have shown that inhibiting ERAP1 can lead to a reduction in the formation of new blood vessels, which is a critical step in the development of metastasis.

In addition to its role in cancer, ERAP1 is also involved in the regulation of other cellular processes that are important for human health. For example, ERAP1 has been shown to be involved in the regulation of protein synthesis, which is a critical step in the development and maintenance of cellular proteins. Additionally, ERAP1 has been shown to be involved in the regulation of cell death, which is an important part of cellular homeostasis.

Given the involvement of ERAP1 in so many cellular processes that are important for human health, it is a promising target for drug development. Researchers are currently working to identify small molecules that can inhibit ERAP1's activity, with the hope of developing new treatments for a variety of diseases.

In conclusion, ERAP1 is a protein that is expressed in most tissues of the body and is involved in the regulation of various cellular processes that are important for human health. Its role in the regulation of cell cycle progression, protein synthesis, and cell death makes it a promising target for drug development. While more research is needed to fully understand the functions of ERAP1 and its potential as a drug target, its potential as a treatment for a variety of diseases is an exciting area of research.

Protein Name: Endoplasmic Reticulum Aminopeptidase 1

Functions: Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Strongly prefers substrates 9-16 residues long. Rapidly degrades 13-mer to a 9-mer and then stops. Preferentially hydrolyzes the residue Leu and peptides with a hydrophobic C-terminus, while it has weak activity toward peptides with charged C-terminus. May play a role in the inactivation of peptide hormones. May be involved in the regulation of blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney

The "ERAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets